A. F. Shields

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

Mark S. Roh, Greg Yothers, M J O'Connell et al. · Journal of Clinical Oncology · 2011 · 194 citations

Surgical Oncology, Preoperative Multimodality Treatment, Oral Capecitabine +17

Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.

Steven R. Alberts, Daniel J. Sargent, T. C. Smyrk et al. · Journal of Clinical Oncology · 2010 · 99 citations

Kras Wild-type, Cra3507 Background, Surgical Oncology +14

Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147.

Richard M. Goldberg, Daniel J. Sargent, S. N. Thibodeau et al. · Journal of Clinical Oncology · 2010 · 54 citations

Surgical Oncology, Adjuvant Mfolfox6, Immunology +16

Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

Jeffrey A. Sloan, M. R. Mahoney, Daniel J. Sargent et al. · Journal of Clinical Oncology · 2011 · 22 citations

A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer

B. F. El-Rayes, Nazik Hammad, P. A. Philip et al. · Journal of Clinical Oncology · 2008 · 11 citations

Tumor Biology, Esophageal Cancer, Gastroesophageal Junction +15